PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects - Test2 - elhamkhani - TriplyDB

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

http://www.wikidata.org/entity/Q35552005

about

Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications Cyanobacterial Toxins of the Laurentian Great Lakes, Their Toxicological Effects, and Numerical Limits in Drinking Water The role of SET/I2PP2A in canine mammary tumors.Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.Mechanisms of doxorubicin resistance in hepatocellular carcinoma Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.Upregulation of PP2Ac predicts poor prognosis and contributes to aggressiveness in hepatocellular carcinoma Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer Zinc Finger and X-Linked Factor (ZFX) Binds to Human SET Transcript 2 Promoter and Transactivates SET Expression.Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.Persistent phosphorylation at specific H3 serine residues involved in chemical carcinogen-induced cell transformation.Functional characterization of AMP-activated protein kinase signaling in tumorigenesis.Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer.Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction.Sphingosine kinase 1 in breast cancer.Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.Therapeutic Targeting of PP2A.Functional importance of PP2A regulatory subunit loss in breast cancer.PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts.Transient PP2A inhibition alleviates normal tissue stem cell susceptibility to cell death during radiotherapy.Forskolin increases the effect of everolimus on aromatase inhibitor-resistant breast cancer cells.SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment Circular RNAs: Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma

P2860

Q28076060-C2EF5BD7-0A02-4100-8AF9-CF3E3FC5FEE2 Q33833344-9A99908B-3DE9-4BD9-AF01-7647DA7EF810 Q33842870-5A19C606-0BC7-4EA0-B0B1-9A2BB3A41EEF Q36020877-A6DDC5D4-CEA9-4C19-9332-03F8D6F33E78 Q36687760-40FAC8A5-4038-4042-B38F-35B8FD5B2AFD Q36796805-DF266741-80EB-4891-A08C-3B796BB86038 Q36844274-51AF0637-1E3C-4BE9-81FD-128EFDA45C80 Q36862936-813C1A18-0E3E-4D23-9489-DC7270D7030D Q37377505-3903AA6C-AA4A-40CC-B306-F58AA255D023 Q38678579-F29AE30C-5162-48BD-90A0-DC82A86B4A0A Q38725299-9A794C26-4ECA-4577-B727-C5D6B401DDC0 Q38807302-F888FD77-571A-40D6-AAE3-E8FBA6251C9C Q38869675-AC108C01-7CB0-445C-8313-C6CC46A9DBD0 Q41146983-C7F2F673-67EA-4C0E-B379-59B8AAA9BF9B Q41976132-D9F467B9-54C4-4331-BA00-A5C2DAE7EB39 Q45070648-09453875-3B5E-42CE-AF32-EB543BE46864 Q47110143-67F98598-B479-46AA-8303-0AF4CC2FE22B Q47271622-669CEA52-EA43-42CC-B107-472DDDAE50C2 Q47436859-D73D627D-E0D3-446B-A6B4-3A4639BF44E8 Q47571869-BCA84419-719A-4973-9E2C-64F2EE5FFBA5 Q48128686-72F38964-C78C-45D1-A82F-ED0B15C8C232 Q52714457-BBF2E281-C39F-4EC3-84F2-D9E3611A2FC9 Q52715830-BABD94F0-6997-4A6D-BEF8-274479EFD671 Q55267752-C8A2E6BB-7411-4074-88A0-3ABAB1FCF4F2 Q58697376-CCC87F98-16FD-44C8-B9A4-EEF9891E04E7 Q58802907-84573DE6-18C0-40F4-83D9-BACE8F96DA65

P2860

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects

http://www.wikidata.org/entity/Q35552005

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

PP2A inhibition determines poo ...... promising therapeutic effects

@ast

PP2A inhibition determines poo ...... promising therapeutic effects

@en

type

label

PP2A inhibition determines poo ...... promising therapeutic effects

@ast

PP2A inhibition determines poo ...... promising therapeutic effects

@en

prefLabel

PP2A inhibition determines poo ...... promising therapeutic effects

@ast

PP2A inhibition determines poo ...... promising therapeutic effects

@en

P1433

Q35552005-1215FD39-E392-41AF-8595-0A62E5E214DD

P1476

Q35552005-09FDD67F-1F4D-4A62-AC78-CEA3A53982AE

P2093

Q35552005-159B70F7-03D3-43CF-875A-A75A90C43C35

Q35552005-43B466D6-33A4-4A90-9E5E-EFAEE09E783C

Q35552005-4AF596DD-DE59-4579-993C-93E024E6C122

Q35552005-539052C6-E7AA-4456-9298-6E00AE9A838E

Q35552005-84E737B7-53DB-4248-93A2-3E2678909E06

Q35552005-C43DAAA0-DD2F-4B72-9DBD-DA5B442AE9B9

Q35552005-CCA0BC84-AE02-4EB0-8AFB-03C0417F0F0C

Q35552005-D4EF5A77-DDEA-44B0-9081-4E3364BF6899

Q35552005-D93CC7D5-F701-411E-B7CB-977A90A2CDF1

Q35552005-F5B1EADB-B378-4AAA-98F9-DD4720B65366

P2860

Q35552005-052A3877-0FF1-44DE-B8F5-7BD45BC6656F

Q35552005-07F698A4-1831-40F7-B71E-7ADCD7C1852D

Q35552005-09780428-5282-46FD-AFBA-48FE1C79ED6C

Q35552005-1675E58E-808D-419F-A168-71C6CF30E59C

Q35552005-1B806304-0EF2-4A43-AC9F-3C591962DB01

Q35552005-1C4D69A3-28D3-498C-BF54-2E936FA7D5F0

Q35552005-217C8A7D-6ADA-4608-9573-5D0EEF8FE9C7

Q35552005-22556A7D-0CE4-4D9D-B816-DC2DC3A103FF

Q35552005-22ED31BB-3849-4F03-80D8-6EFF71A641E2

Q35552005-248E11A6-1B53-4223-A2E9-8F0E1C8452EA

P304

Q35552005-A970B2DF-EAA8-43F4-9F2F-AC6EEF2CF1DC

P31

Q35552005-F96BDCF5-F444-4FC1-ADFA-0BE3177F0790

P356

Q35552005-DAECD984-3895-48C9-9279-9825C67FFED2

P407

Q35552005-1E678647-8F3F-4A94-97B0-561428C34466

P433

Q35552005-21D5F53E-076A-482F-B46E-A537AEF42857

P478

Q35552005-645DC81C-BE2B-45B4-BE3D-ED756DA49D30

P50

Q35552005-192DA951-6E0E-43B5-BD7D-567181086FB3

Q35552005-1A9199EA-9F4F-49B6-9BC8-F36C121B370B

Q35552005-F6539E2B-9C85-4305-A736-143248ED55BA

P577

Q35552005-D80E5098-0690-4354-9443-815817D2525B

P5875

Q35552005-B53F4072-AD5F-4EBB-8D2E-F619259E90D5

P698

Q35552005-D7533473-FA74-4DC8-8662-3EA6D033DC20

P932

Q35552005-02C7C19E-D511-4FCF-8742-90B035708B47

P356

ONCOTARGET.3012

P1433

P1476

PP2A inhibition determines poo ...... promising therapeutic effects

@en

P2093

Ana Rovira

http://www.w3.org/2001/XMLSchema#string

Ion Cristóbal

http://www.w3.org/2001/XMLSchema#string

Jesús García-Foncillas

http://www.w3.org/2001/XMLSchema#string

Joan Albanell

http://www.w3.org/2001/XMLSchema#string

Juan Madoz-Gúrpide

http://www.w3.org/2001/XMLSchema#string

Oriol Arpí

http://www.w3.org/2001/XMLSchema#string

Pilar Eroles

http://www.w3.org/2001/XMLSchema#string

Rebeca Manso

http://www.w3.org/2001/XMLSchema#string

Sandra Zazo

http://www.w3.org/2001/XMLSchema#string

Silvia Menéndez

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Molecular portraits of human breast tumours

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

PP2A: unveiling a reluctant tumor suppressor.

P304

4299-4314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.3012

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273004596

http://www.w3.org/2001/XMLSchema#string

P698

25726524

http://www.w3.org/2001/XMLSchema#string

P932

4414191

http://www.w3.org/2001/XMLSchema#string